Core B will provide a constant resource of mice harboring melanomas that express BRAF*, including pairs of tumor biopsies that are sensitive or resistant to BRAFi. The integrative power of this core lies in interacting and intersecting with parallel samples from human melanomas in Core A, providing cross-species triangulation of genetic elements that confer tumor microenvironment-specific phenotypic effects. This core will provide not only a bank of Braf* mouse (iBIP and M3) melanoma tissues and derivative cell lines collected at baseline, post-treatment and upon relapse, but also capability to engineer new alleles ex vivo and perform preclinical therapeutic studies. The immunocompetent background and natural tumor microenvironment setting of IBIP melanomas bring a key feature to this TMEN center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163125-04
Application #
8744892
Study Section
Special Emphasis Panel (ZCA1-SRLB-3)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
4
Fiscal Year
2014
Total Cost
$91,116
Indirect Cost
$13,680
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wargo, Jennifer A; Cooper, Zachary A; Flaherty, Keith T (2014) Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov 4:1377-86
Smith, Michael P; Sanchez-Laorden, Berta; O'Brien, Kate et al. (2014) The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF?. Cancer Discov 4:1214-29
Cooper, Zachary A; Juneja, Vikram R; Sage, Peter T et al. (2014) Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2:643-54
Shi, Min; Roemer, Margaretha G M; Chapuy, Bjoern et al. (2014) Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 38:1715-23
Sullivan, Ryan J; Lorusso, Patricia M; Flaherty, Keith T (2013) The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 19:5283-91
Frederick, Dennie T; Piris, Adriano; Cogdill, Alexandria P et al. (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19:1225-31
Chen, Benjamin J; Chapuy, Bjoern; Ouyang, Jing et al. (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19:3462-73